NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-08-31
Reading PFE? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Warn: Primary pillar under pressure — Full-year 2026 revenue in range $59.5 to $62.5 billion: FY26 revenue guidance $60.5B-$62.5B vs target $59.5B.
Pfizer keeps its full-year 2026 revenue guidance of up to $62.5 billion. Adjusted EPS is expected between $2.80 and $3.00. The company targets $5.7 billion in cost savings by 2027. New acquisitions and approvals support growth in rare diseases and oncology.
Drug pricing pressures in key markets like Germany could reduce future revenues. Revenue growth is expected to decline about 4% next year. Cost savings may not fully offset margin pressures. CFO transition adds uncertainty to execution.
The market prices Pfizer about 25% below our fair value near $32. Analysts expect about -4% revenue growth. Our fair value is roughly 20% above the Street median, reflecting more optimism on growth and cost savings.
Breaks if: Adjusted EPS falls below $2.80 or above $3.00
Maintain and update full-year 2026 revenue guidance in the range of $60.5 to $62.5 billion and adjusted diluted EPS guidance of $2.80 to $3.00.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
Pfizer represents a durable compounder with a focus on steady growth and cost savings. The current thesis remains intact, supported by robust earnings quality and a stable management team.
The market currently prices Pfizer as cheap compared to its peers, with a low expectations gap. There is a justified valuation, indicating that investors are not overly optimistic about future performance.
Fundamentals are likely to show continued operational growth, as management has reaffirmed its financial guidance and is on track with cost-saving initiatives. However, there is a moderate risk due to recent earnings surprises trending down.
The thesis hinges on key factors such as the performance of sector bellwethers and the company's ability to maintain or raise guidance in upcoming calls. Additionally, broader economic conditions, particularly job reports, could impact sentiment.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company beat earnings expectations recently. It reaffirmed its full-year 2026 financial guidance. However, it faces increased legal liability risks from new lawsuits. This could raise costs and affect investor confidence.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 5 of last 5 quarters. Pfizer raised full-year 2026 revenue guidance by $500 million at the midpoint from $59.5 billion to $60.5 billion while reaffirming adjusted diluted EPS guidance of $2.80 to $3.00. Revenue grew from $13.7B in 2026-Q1 to $15.0B in 2026-Q2 quarterly, reflecting operational growth. The trajectory matches management's repeated reaffirmations and upward revision, indicating delivery on this priority.
“Raises full-year 2026 Revenue guidance by $500 million at the midpoint to a range of $60.5 to $62.5 billion and reaffirms Adjusted diluted EPS guidance of $2.80 to $3.00.”
“Reaffirms all components of full-year 2026 financial guidance including Revenues in a range of $59.5 to $62.5 billion and Adjusted Diluted EPS in a range of $2.80 to $3.00.”
“Reaffirms all components of full-year 2026 guidance including Revenues in a range of $59.5 to $62.5 billion and Adjusted Diluted EPS in a range of $2.80 to $3.00.”
“Reaffirms full-year 2026 financial guidance including Revenues in a range of $59.5 to $62.5 billion and Adjusted Diluted EPS in a range of $2.80 to $3.00.”
“Reaffirms full-year 2026 financial guidance including Revenues in a range of $59.5 to $62.5 billion and Adjusted Diluted EPS in a range of $2.80 to $3.00.”
Breaks if: Dividend payments decline materially or share repurchase authorization withdrawn
Continue capital allocation strategy focused on reinvesting in growth, maintaining and growing dividends, and potential future share repurchases after de-leveraging.
Stated as a priority in 5 of last 5 quarters. Pfizer consistently emphasizes a balanced capital allocation strategy focused on reinvestment, dividend growth, and potential share repurchases after de-levering. The company returned $4.9 billion in dividends in first half 2026 and maintains $3.3 billion in share repurchase authorization with no repurchases completed in 2026. The trajectory shows ongoing delivery on dividend growth and prudent capital deployment.
“Capital allocation framework includes reinvesting, dividend growth, and potential share repurchases after de-levering.”
“Maintaining balanced capital allocation with dividend growth and potential share repurchases after de-levering.”
“Capital allocation based on reinvesting, dividend growth, and potential share repurchases after de-levering.”
“Maintaining balanced capital allocation strategy with dividend growth and potential share repurchases.”
“Capital allocation framework designed to enhance long-term shareholder value with dividends and share repurchases.”
Breaks if: Net cost savings fall short of $5.7 billion by end of 2027
Continue ongoing cost realignment and productivity enhancement initiatives targeting approximately $5.7 billion in net cost savings by end of 2027.
Stated as a priority in 5 of last 5 quarters. Pfizer has consistently targeted approximately $5.7 billion in net cost savings by end of 2027, with $4.5 billion expected by end of 2025 and additional $2.5 billion productivity savings announced in 2026-Q2. Operational expenses showed modest decreases in SI&A expenses over recent quarters, indicating ongoing delivery. The trajectory is delivering with expanded cost savings initiatives.
“Announces additional anticipated productivity enhancement savings of $2.5 billion expected to be realized from 2027 through 2029.”
“Ongoing focus on operational efficiency and cost realignment programs driving productivity gains.”
“On track to deliver approximately $5.7 billion in overall anticipated net cost savings by end of 2027.”
“On track to deliver approximately $7.2 billion in overall anticipated net cost savings by end of 2027.”
“On track to deliver approximately $4.5 billion of net cost savings by end of 2025, with additional savings expected through 2027.”
Breaks if: Material revenue declines due to drug pricing policy changes
Breaks if: Full-year revenue falls below $59.5 billion or above $62.5 billion
Maintain and update full-year 2026 revenue guidance in the range of $60.5 to $62.5 billion and adjusted diluted EPS guidance of $2.80 to $3.00.
Stated as a priority in 5 of last 5 quarters. Pfizer raised full-year 2026 revenue guidance by $500 million at the midpoint from $59.5 billion to $60.5 billion while reaffirming adjusted diluted EPS guidance of $2.80 to $3.00. Revenue grew from $13.7B in 2026-Q1 to $15.0B in 2026-Q2 quarterly, reflecting operational growth. The trajectory matches management's repeated reaffirmations and upward revision, indicating delivery on this priority.
“Raises full-year 2026 Revenue guidance by $500 million at the midpoint to a range of $60.5 to $62.5 billion and reaffirms Adjusted diluted EPS guidance of $2.80 to $3.00.”
“Reaffirms all components of full-year 2026 financial guidance including Revenues in a range of $59.5 to $62.5 billion and Adjusted Diluted EPS in a range of $2.80 to $3.00.”
“Reaffirms all components of full-year 2026 guidance including Revenues in a range of $59.5 to $62.5 billion and Adjusted Diluted EPS in a range of $2.80 to $3.00.”
“Reaffirms full-year 2026 financial guidance including Revenues in a range of $59.5 to $62.5 billion and Adjusted Diluted EPS in a range of $2.80 to $3.00.”
“Reaffirms full-year 2026 financial guidance including Revenues in a range of $59.5 to $62.5 billion and Adjusted Diluted EPS in a range of $2.80 to $3.00.”
Overall, the outlook for Pfizer remains stable over the next 1 to 3 years, with a focus on execution and sector dynamics. Not investment advice.
